Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Intercept Pharmaceuticals
Biotech
Enanta pulls plug on NASH, seeks to offload assets for combos
After getting a look at interim phase 2b data, the biotech has decided to stop the monotherapy trial and seek to outlicense its candidates.
Nick Paul Taylor
Oct 4, 2021 8:40am
Ex-Intercept CMO Campagna lands at Q32
Mar 9, 2021 8:45am
Intercept loses chief medical officer months after CEO's exit
Feb 23, 2021 7:20am
CymaBay tees up new phase 3 study for resurrected liver drug
Nov 16, 2020 8:04pm
After disastrous NASH crash, Genfit slashes jobs and splits ops
Oct 1, 2020 7:45am
COVID-19 unlikely to 'significantly delay' Genfit's NASH data
Mar 31, 2020 8:43am
